Atypical HUS, in contrast, is a rare but devastating disease that can affect individuals of any age, from infancy to adulthood. Its name, "atypical," belies its clinical gravity. Unlike typical HUS, aHUS is not preceded by STEC infection. Instead, it is a primary disease of uncontrolled complement activation. In the majority of cases, aHUS is caused by inherited genetic mutations in complement regulatory proteins (e.g., factor H, factor I, MCP) or in activating proteins (e.g., factor B, C3). These mutations lead to a state of chronic, unchecked activation of the alternative complement pathway, resulting in persistent attack on the endothelium.
Typical HUS, often referred to as Shiga toxin-associated HUS or Diarrhea-positive (D+) HUS, is the most common form of the syndrome, particularly in children. typical vs atypical hemolytic uremic syndrome
Hemolytic Uremic Syndrome (HUS) is a complex and potentially life-threatening condition characterized by a triad of symptoms: hemolytic anemia (destruction of red blood cells), thrombocytopenia (low platelet count), and acute kidney injury. Atypical HUS, in contrast, is a rare but
Hemolytic Uremic Syndrome (HUS) is a complex group of rare blood disorders characterized by a triad of symptoms: (destruction of red blood cells), thrombocytopenia (low platelet count), and acute kidney injury (AKI) . While they share these core features, typical and atypical HUS differ significantly in their causes, progression, and treatment. Comparing Typical and Atypical HUS P102 Typical vs atypical hemolytic-uremic syndrome Instead, it is a primary disease of uncontrolled
| Feature | Typical HUS (Shiga-Toxin) | Atypical HUS (aHUS) | | :--- | :--- | :--- | | | Infectious (STEC E. coli ) | Genetic / Complement Dysregulation | | Prodrome | Bloody Diarrhea (D+) | Often absent; insidious onset | | Age Group | Predominantly children | All ages (adults and children) | | Mechanism | Toxin-mediated endothelial damage | Uncontrolled immune system activation | | Seasonality | Summer months (picnic season) | No seasonal pattern | | Primary Treatment | Supportive care (fluids, dialysis) | Complement inhibitors (e.g., Eculizumab) | | Recurrence | Rare (immunity to strain develops) | Common (lifelong predisposition) | | Prognosis | Generally good; high recovery rate | Historically poor; improved with biologics |
| Feature | Typical HUS (tHUS) | Atypical HUS (aHUS) | | --- | --- | --- | | | Children < 5 years | Any age | | Cause | STEC infection | Genetic, autoimmune, infections, pregnancy | | Diarrhea | Common | Variable | | Recurrence | Rare | Common | | Outcome | Generally good | More severe, higher risk of ESRD |